Evaluation of Apelin-13 and Apelin-36 in Women With Recurrent Pregnancy Loss

February 12, 2023 updated by: Ain Shams University

Evaluation of Apelin-13 and Apelin-36 Concentrations in Women With Primary Unexplained Recurrent Pregnancy Loss

Lower Apelin levels are associated with hypertensive disorders with pregnancy, yet no studies investigated its levels in recurrent pregnancy loss

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

88

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
      • Cairo, Egypt, 002
        • AinShams Maternity Hospital
    • Cairo/القاهرة
      • Cairo, Cairo/القاهرة, Egypt, 71350
        • Ain shams university maternity hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 40 years (ADULT)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

Female

Sampling Method

Non-Probability Sample

Study Population

Pregnant females in first trimester

Description

Inclusion Criteria:

  • pregnant women in first trimester
  • negative antiphospholipid markers
  • normal karyotype

Exclusion Criteria:

  • multiple pregnancy
  • fetal malformations
  • maternal diseases
  • smoking or alcohol use
  • history of or risk factors for preterm labor

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Healthy
Diagnostic test: Apelin-13, Apelin-36
Serum levels of Apelin-13 and Apelin-36
Recurrent pregnancy loss
Diagnostic test: Apelin-13, Apelin-36
Serum levels of Apelin-13 and Apelin-36

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Apelin-13 and Apelin-36
Time Frame: 1 year
Serum levels of Apelin-13 and Apelin-36
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Ain Shams University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

January 23, 2022

Primary Completion (ACTUAL)

January 30, 2023

Study Completion (ACTUAL)

January 30, 2023

Study Registration Dates

First Submitted

January 11, 2022

First Submitted That Met QC Criteria

January 11, 2022

First Posted (ACTUAL)

January 24, 2022

Study Record Updates

Last Update Posted (ESTIMATE)

February 14, 2023

Last Update Submitted That Met QC Criteria

February 12, 2023

Last Verified

February 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • MS 672/2021

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Recurrent Pregnancy Loss

Clinical Trials on Apelin-13, Apelin-36

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zimbabwe

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe